immune-checkpoint

Documents about immune-checkpoint

• Engineered T cells achieve durable persistence in the brain by clearing a state-selective checkpoint that governs neuroimmune privilege#651690eScholarship
• A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma#827885ClinicalTrials.gov
• Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas#855865ClinicalTrials.gov
• Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC#896675ClinicalTrials.gov
• Cancer Panel From Blood of Lung Cancer Patients#900850ClinicalTrials.gov
• Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC#1015719Europe PMC
• [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer#1048040ClinicalTrials.gov
• Gender matters. Sex-related differences in immunotherapy outcome in patients with non-small cell lung cancer#330406IRIS
• Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer#880806ClinicalTrials.gov
• Nivolumab in Children and Adults With Nasopharyngeal Carcinoma#893983ClinicalTrials.gov
• Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors#966970ClinicalTrials.gov
• The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer#226258ClinicalTrials.gov
• Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer#332741ClinicalTrials.gov
• Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition#633727ClinicalTrials.gov
• Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma#837592ClinicalTrials.gov
• Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors#845785ClinicalTrials.gov
• Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response#845838ClinicalTrials.gov
• Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma#911900ClinicalTrials.gov
• Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer#982117ClinicalTrials.gov
• ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)#279487ClinicalTrials.gov
• Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade#346913ClinicalTrials.gov
• Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer#377424ClinicalTrials.gov
• Prolonged TNF-α stimulation induces a PD-1–associated exhaustion-like phenotype in mesenchymal stromal cells#481122OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer#885894ClinicalTrials.gov
• Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma#914260ClinicalTrials.gov
• A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary#981766ClinicalTrials.gov
• Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy#140999ClinicalTrials.gov
• Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications#308335HAL (France)
• Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression#807651ClinicalTrials.gov
• Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)#828325ClinicalTrials.gov
• Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN#852664ClinicalTrials.gov
• The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?#215411HAL (France)
• PD-1/PD-L1 in Myocarditis Transcriptional Signals, Functional Questions#675875eScholarship
• The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial#811414ClinicalTrials.gov
• Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers#891741ClinicalTrials.gov
• Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)#905792ClinicalTrials.gov
• Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis#936032Repositorio de Universidad Autónoma de Chile.
• Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform#121327ClinicalTrials.gov
• How to best exploit immunotherapeutics in advanced gastric cancer: between biomarkers and novel cell-based approaches#250634IRIS
• Gut Microbiota (GM) Biodiversity in Patients With Solid Tumors Treated With Immune Checkpoint Inhibitors (ICIs): a Monocenter Prospective Study to Identify the Interactions Between GM and ICIs#307436ClinicalTrials.gov
• Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer#843388ClinicalTrials.gov
• Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma#864096ClinicalTrials.gov
• A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma#891611ClinicalTrials.gov
• Table 1_Case Report: Contrast-enhanced ultrasonography for evaluating a newly detected contralateral pulmonary lesion during non-small cell lung cancer chemoimmunotherapy.docx#210838Figshare
• Data Sheet 1_Nivolumab in previously treated metastatic renal cell carcinoma: real-world data from the Czech Republic and Slovakia.docx#322286Figshare
• Modulation of the response to immunotherapy in triple-negative breast cancer: the role of the microbiota and microbial metabolites in the tumor microenvironment#642682Europe PMC
• Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study#836745ClinicalTrials.gov
• Image 2_Multimodal characterization of HLA-G expression across solid tumors reveals transcript-protein discordance and implications for immunotherapy targeting.tif#1065628Figshare
• Image 1_Multimodal characterization of HLA-G expression across solid tumors reveals transcript-protein discordance and implications for immunotherapy targeting.tif#1065629Figshare
• Neoadjuvant chemo-immunotherapy in a kidney transplant recipient with locally advanced non-small cell lung cancer: a case report of a therapeutic dilemma#308243HAL (France)